Health ❯ Healthcare

Pharmaceuticals

Drug Development Drug Approval Drug Safety Clinical Trials Drug Pricing Weight Loss Cancer Treatment Drug Regulation Medications Weight Loss Drugs

Novo Nordisk Sues Lilly Over Weight‑Loss Ads as GLP‑1 Rivalry Intensifies

The case seeks to curb Eli Lilly’s consumer ads and could change how head‑to‑head trial results are shown to patients and prescribers.

FDA Authorizes Intermountain to Give Investigational KRAS Drug to Pancreatic Cancer Patients

HSE Drugs Group Recommends Against Funding Skyclarys as Final Vote Looms

UK Regulator Approves Eli Lilly’s Foundayo Tablet for Weight Loss and Type 2 Diabetes

One-Time Triple Regimen Clears HIV in Infant Macaque Model

AbCellera’s Menopause Antibody Hits Phase 2 Goals

Lilly Posts Blowout Quarter as Global GLP‑1 Push Tests Price‑for‑Volume Strategy

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

Sionna Halts SION-719 After Mid-Stage Cystic Fibrosis Trial Misses Key Biomarker

FDA Approves Moderna’s mFlusiva for Adults 50 and Older

Bank of America Says It Pays Over $250 Million a Year for GLP‑1 Drugs

FDA Grants Accelerated Approval for RP1 (Tudriqev) With Nivolumab in Advanced Melanoma

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Lilly Pulls Further Ahead in GLP-1 Race After Blowout Quarter

FDA Approves Orzeyful as First Orexin Agonist for Narcolepsy Type 1

Retailers Move to Fill $50 Medicare GLP‑1 Prescriptions

Reuters Says There Were No AstraZeneca‑Bristol Myers Merger Talks

Gracie McGraw Says Ozempic 'Brought Back' Her Eating Disorder

BioCryst Cuts Internal Discovery After Q2 ORLADEYO Gains and Pediatric Rollout

Eli Lilly Opens Limited Early Access to Experimental Obesity Drug Retatrutide